Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.46 |
| ▸ | INSR | P06213 | 11/20 | 0.46 |
| ▸ | IGF1R | P08069 | 8/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729784 | 0.93 | INSR (0.52) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12780190 | 0.88 | EGFR (0.48) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12781937 | 0.85 | ALK (0.46) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12780208 | 0.85 | ALK (0.46) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12917664 | 0.84 | ULK1 (0.53) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12728737 | 0.83 | ALK (0.59) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12729786 | 0.81 | ALK (0.57) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12780660 | 0.81 | ALK (0.55) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL10207506 | 0.79 | ALK (0.60) | PLK1ALKINSRIGF1RAURKA | |
| SCHEMBL12729763 | 0.79 | PTK2 (0.61) | PLK1ALKINSRIGF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | PLK1 968/4885ALK 3384/4885INSR 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.